Detection kit for hyperglycosylated modification of hCG (human chorionic gonadotropin) tumor marker

Abstract

The invention relates to a detection kit for hyperglycosylated modification of an hCG (human chorionic gonadotropin) tumor marker. According to the detection kit, magnetic beads are combined with an antibody (MCA-A) to serve as a capture antibody to capture total hCG in a to-be-detected sample, wherein the affinity of the antibody (MCA-A) is least influenced by glycosylation change; an antibody (MCA-B) most influenced by glycosylation change and another antibody (MCA-C) less influenced by glycosylation are used for detecting the total protein content and the N-glycosylation modification degree of hCG in the sample simultaneously, so that a tumor biomarker is identified. The detection kit improves the accuracy, the sensitivity and the specificity of an immunodiagnosis method greatly and has great practical value for detection of hyperglycosylated modification of the tumor marker in the actual sample.

Description

technical field [0001] The invention relates to a detection kit for hyperglycosylation modification (hCG-H) of human chorionic gonadotropin (hCG) tumor marker, in particular to a method for simultaneously detecting hCG and hCG-H in disease materials by combining different antibodies The detection kit belongs to the technical field of tumor immunodiagnosis. Background technique [0002] Tumors and cancers are one of the major diseases that seriously threaten human health. Early detection and diagnosis as well as the selection of correct treatment methods are the key to the prevention and treatment of tumors and cancers. Many cancer patients have changes in the level and structure of certain biomolecules, which can often be used as biomarkers for discovering cancer. A substantial portion of these biomarkers are glycoproteins. Glycoproteins in many diseases, especially tumors, will experience abnormal glycosylation phenomena such as longer sugar chains, more branches, and mor...

AI Technical Summary

Problems solved by technology

[0003] (1) Existing immunodiagnostic reagents are based on the assumption that the binding ability of markers and antibodies is not affected by glycosylation, and individual differences in patient hCG glycosylation are not considered

However, glycosylation may change the structure of the protein, thereby affecting the affinity of the antigen and the antibody, and ultimately lead to deviations in the measurement results

[0004] (2) The existing immunodiagnostic reagent products can only quantitatively analyze the total protein content of the biomarker hCG, but cannot structurally distinguish hCG-H with abnormal glycosylation from ordinary hCG

[0006] Although there are reports of antibodies that can specifically recognize hCGCore2 O-glycosylation abnormalities, antibodies that can directly recognize abnormal N-glycosylation modifications in hCG in cancer patients have not yet been found, mainly due to the microscopic changes in N-glycosylation modifications. Heterogeneity and weak immunogenicity

Images